COMMUNIQUÉS West-GlobeNewswire

Experts at Park Mental Health Announce New Therapeutic Approach: Highlighting the Role of Community Support in Recovery
10/03/2026
Park Mental Health highlights the importance of supportive relationships in mental health journey SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- It can be a difficult task to support an individual struggling with mental [...]
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
10/03/2026
Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 [...]
Egg Medical Presents CRT 2026 Data Demonstrating a Responsible Path to Light Lead and Lead-Apron Free Protection
10/03/2026
WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- Egg Medical, a leader in enhanced radiation protection devices (ERPD), today announced the results of a Late-Breaking Trial presented at the Cardiovascular Research [...]
SS Innovations Reports Fourth Quarter and Full Year 2025 Financial Results
10/03/2026
Strong growth in SSi Mantra installations, procedures and revenues FORT LAUDERDALE, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII) , a [...]
Roche Annual General Meeting 2026
10/03/2026
Shareholders approved all proposals of the Board of Directors Severin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed 39th consecutive dividend [...]
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
10/03/2026
— The new pricing structure is made available as of February for 32,13 SEK per day at pharmacies throughout Sweden AMSTERDAM, March 10, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical [...]
SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails
10/03/2026
TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company [...]
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
10/03/2026
ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatment Children ages 2-5 who achieved disease clearance and who switched to proactive twice- [...]
Assemblée générale annuelle 2026 de Roche
10/03/2026
Adoption de toutes les propositions du Conseil d’administration Réélection de Severin Schwan à la présidence du Conseil d’administration ; confirmation de tous les autres membres du Conseil d’administration qui se sont [...]
Longeveron Announces Private Placement of up to $30 Million
10/03/2026
$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules [...]
Imprivata Introduces Agentic Identity Management to Secure and Govern AI Agents in Healthcare
10/03/2026
New capabilities enable healthcare organizations to deploy AI agents that improve clinician productivity while maintaining secure, compliant access across modern and legacy systems WALTHAM, Mass., March 10, 2026 (GLOBE [...]
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026
10/03/2026
SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]
Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026
10/03/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES 10 MARCH 2026 at 13.50 EET Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026 In accordance with a decision by the Board of [...]
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
10/03/2026
Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced [...]
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
10/03/2026
Results demonstrated early signals of C-peptide preservation T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Phase 1 data MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- SAB [...]
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
10/03/2026
Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvements in strength [...]
Trinity Biotech Announces Further Major Technical Breakthroughs in Advancing Next Generation CGM+ Platform
10/03/2026
- Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of pivotal clinical trial in 2026 - Updated electronics architecture delivers [...]
CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering
10/03/2026
ZUG, Switzerland and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other factors, $350 million [...]
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
10/03/2026
WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]

Pages